JP2012512165A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512165A5
JP2012512165A5 JP2011540922A JP2011540922A JP2012512165A5 JP 2012512165 A5 JP2012512165 A5 JP 2012512165A5 JP 2011540922 A JP2011540922 A JP 2011540922A JP 2011540922 A JP2011540922 A JP 2011540922A JP 2012512165 A5 JP2012512165 A5 JP 2012512165A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
arylalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011540922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067673 external-priority patent/WO2010068867A1/en
Publication of JP2012512165A publication Critical patent/JP2012512165A/ja
Publication of JP2012512165A5 publication Critical patent/JP2012512165A5/ja
Pending legal-status Critical Current

Links

JP2011540922A 2008-12-11 2009-12-11 四環系ピラジノインドールを用いた多発性硬化症の治療方法 Pending JP2012512165A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12157408P 2008-12-11 2008-12-11
US61/121,574 2008-12-11
US23323509P 2009-08-12 2009-08-12
US61/233,235 2009-08-12
PCT/US2009/067673 WO2010068867A1 (en) 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles

Publications (2)

Publication Number Publication Date
JP2012512165A JP2012512165A (ja) 2012-05-31
JP2012512165A5 true JP2012512165A5 (cg-RX-API-DMAC7.html) 2013-01-31

Family

ID=42243090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540922A Pending JP2012512165A (ja) 2008-12-11 2009-12-11 四環系ピラジノインドールを用いた多発性硬化症の治療方法

Country Status (9)

Country Link
US (1) US20110268699A1 (cg-RX-API-DMAC7.html)
EP (1) EP2375900B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012512165A (cg-RX-API-DMAC7.html)
CN (1) CN102395275A (cg-RX-API-DMAC7.html)
AU (1) AU2009324495B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922871A2 (cg-RX-API-DMAC7.html)
CA (1) CA2747235C (cg-RX-API-DMAC7.html)
IL (1) IL213476A0 (cg-RX-API-DMAC7.html)
WO (1) WO2010068867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031054A1 (en) 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
US10154983B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
US10058522B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
WO2013130422A1 (en) * 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
KR20150119227A (ko) * 2013-02-15 2015-10-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
KR101521807B1 (ko) * 2014-01-20 2015-05-20 한국전자통신연구원 데이터 전송 제어 장치 및 그 방법
ES2988983T3 (es) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico Medicinal S Sales de mandelato de enantiómeros de pirlindol para uso en medicina
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
EP3520803A1 (en) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Novel uses
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESSES FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO2004098638A1 (ja) * 2003-05-06 2004-11-18 Ono Pharmaceutical Co., Ltd. エフェクター細胞機能阻害剤
RU2281085C2 (ru) * 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
MX2008000811A (es) * 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.
MX2009012788A (es) * 2007-05-25 2010-01-14 Medivation Neurology Inc Metodos y composiciones para estimular celulas.

Similar Documents

Publication Publication Date Title
JP2012505257A5 (cg-RX-API-DMAC7.html)
JP2009504764A5 (cg-RX-API-DMAC7.html)
JP2010511721A5 (cg-RX-API-DMAC7.html)
JP2011500725A5 (cg-RX-API-DMAC7.html)
JP2008508289A5 (cg-RX-API-DMAC7.html)
JP2017528524A5 (cg-RX-API-DMAC7.html)
JP2008507538A5 (cg-RX-API-DMAC7.html)
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2007517807A5 (cg-RX-API-DMAC7.html)
JP2010513523A5 (cg-RX-API-DMAC7.html)
JP2011515482A5 (cg-RX-API-DMAC7.html)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2008512490A5 (cg-RX-API-DMAC7.html)
JP2012515225A5 (cg-RX-API-DMAC7.html)
JP2005519083A5 (cg-RX-API-DMAC7.html)
ATE383360T1 (de) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
TW200621249A (en) Substituted amide beta secretase inhibitors
JP2018502925A5 (cg-RX-API-DMAC7.html)
JP2014511893A5 (cg-RX-API-DMAC7.html)
RU2009135277A (ru) Гетероциклические ингибиторы аспартильной протеазы
JP2011513410A5 (cg-RX-API-DMAC7.html)
JP2012510502A5 (cg-RX-API-DMAC7.html)
JP2020523388A5 (cg-RX-API-DMAC7.html)
JP2014530881A5 (cg-RX-API-DMAC7.html)
JP2009542683A5 (cg-RX-API-DMAC7.html)